Literature DB >> 2102260

Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media.

W A De Waal1, F J Maessen, J C Kraak.   

Abstract

The methods for analysis of platinum-based anti-cancer drugs in biological media are reviewed in this paper. Although emphasis is placed on cisplatin, attention is also given to several of its analogues (carboplatin, iproplatin) and their degradation and biotransformation products. In an introductory section a short description is given of the historical background and the clinical applications of cisplatin. Reactions occurring in the body and in aqueous solutions are discussed because of their implications for the design of analytical procedures. After a detailed description of sample preparation and storage, attention is focussed on the analytical techniques used for the determination of either total platinum levels or individual platinum-containing compounds. The techniques discussed include atomic absorption and emission spectrometry, derivatization reactions and several chromatographic techniques with different detection methods. The specific advantages and disadvantages of these techniques are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2102260     DOI: 10.1016/0731-7085(90)80003-8

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates.

Authors:  W W Bullen; L D Andress; T Chang; L R Whitfield; M L Welch; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

Authors:  P H Cashin; H Ehrsson; I Wallin; P Nygren; H Mahteme
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

4.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Authors:  D C Thompson; A Vaisman; M K Sakata; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.